Cite
HARVARD Citation
Butzkueven, H. et al. (2021). Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). Multiple sclerosis. pp. 410-419. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Butzkueven, H. et al. (2021). Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). Multiple sclerosis. pp. 410-419. [Online].